SH

Sonal Hiteshkumar Dave

Active Director Director DIN 08171131
DIN 08171131 First appointment Jul 2018 Primary industry Trading
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2018
Shareholding value β€’β€’β€’β€’ Premium profile

About Sonal Hiteshkumar Dave

Data last updated:

Sonal Hiteshkumar Dave is a Director at Rensat Pharma Private Limited (since 2018). The company operates in Trading.

DIN 08171131
Primary Designation Director
Industry Trading
First Appointment 02 Jul 2018
Oldest Company Age 8 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Rensat Pharma Private Limited U51909GJ2018PTC101735
Director02 Jul 20182018Active

Directorship timeline

Open interactive timeline →
Rensat Pharma Private Limited
Premium access

Shareholding and investment profile for Sonal Hiteshkumar Dave

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sonal Hiteshkumar Dave

Sonal Hiteshkumar Dave currently holds 1 directorship: Rensat Pharma Private Limited (Director, since 02 Jul 2018).

Sonal Hiteshkumar Dave was first appointed on 02 Jul 2018 as Director at Rensat Pharma Private Limited.

The current boards of Sonal Hiteshkumar Dave's companies include Alihusain Noormohmmed Maknojiya (Rensat Pharma Private Limited), Jainish Acharya Bharatbhai (Rensat Pharma Private Limited), Maheshbhai Acharya Dalpatbhai (Rensat Pharma Private Limited), Ramilaben Ghemarbhai Chaudhari (Rensat Pharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available